Amarin Corporation plc (NASDAQ: AMRN) is trading in the red early on in the pre-market hours today. However, if you go digging into the news, you’ll quickly find that the only bit of news that was released this morning was positive. Nonetheless, the stock is trading in the red, creating what I believe to be an opportunity to get in on the gains at a discount. Today, we’ll talk about the data, what we’re seeing from the stock, and what we’ll be watching for ahead.
AMRN Announces Positive Clinical Data
As mentioned above, Amarin is having a relatively rough start to the trading session this morning, but the news that was released was positive. Recently, the company provided data from its cardiovascular outcomes trial known as REDUCE-IT. The data was presented at the 2018 Scientific Sessions of the American Heart Association (AHA) in Chicago over the weekend. Here’s what we saw:
AMRN said that landmark cardiovascular risk reduction benefit show in the trial are the largest of any major cardiovascular outcome study of a drug that is intended to address residual cardiovascular risk that remains after cholesterol management. The treatment, vascepa, showed drastic reductions in cardiovascular risk including:
- a 20% reduction in the risk of cardiovascular death,
- a 31% reduction in risk of fatal or nonfatal heart attacks,
- a 28% reduction in the risk of fatal or nonfatal stroke,
- a 35% reduction of risk of urgent or emergent coronary revascularization,
- a 32% reduction in risk of hospitalization for unstable angina,
The data also show that to date, the treatment has been relatively well tolerated and safe among the patient population it was intended for. In a statement, John F. Thero, President and CEO at AMRN, had the following to offer:
Amarin has spent over $500 million developing Vascepa. We are intently focused on improving patient care. Our priorities are now shifting to educate the world regarding these results so that the pain, loss of productivity and high costs of cardiovascular events can be reduced.
What We’re Seeing From The Stock
In general, when positive news is released, we tend to see gains in the value of the stock that’s representative of the company that released the news. In this case, we’re seeing a bit of an inverse reaction that I believe to be an opportunity to get in on future gains at a discount. Nonetheless, our partners at Trade Ideas were the first to alert us to the movement. At the moment (7:38), AMRN is trading at $20.63 per share after a loss of $0.43 per share or 2.00% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on AMRN. In particular, we’re interested in following the company’s ongoing work to bring vascepa to patients at high risk for cardiovascular events. After all, clinical data continues to support the strong efficacy and favorable safety and tolerability profiles of the treatment. So, this is a very promising asset. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!